Sandoz AG v Bayer Intellectual Property GmbH

Link copied
Case Copied 60 min read

FEDERAL COURT OF AUSTRALIA

Sandoz AG v Bayer Intellectual Property GmbH [2024] FCAFC 135

Appeal from: Sandoz AG v Bayer Intellectual Property GmbH [2023] FCA 1321
File number(s): VID 976 of 2023
Judgment of: YATES, BURLEY AND DOWNES JJ
Date of judgment: 23 October 2024
Catchwords:

PATENTS – whether skilled person could be reasonably expected to have ascertained international patent publication – where patent database would have been one of the databases searched by person skilled in the art – where expert provided with search results which formed a subset of larger set of search results which would have been derived from broader search conducted by person skilled in the art – whether primary judge erred in finding that patent publication would not have been ascertained within meaning of s7(3) Patents Act 1990 (Cth) – error established

PATENTS – whether inventions involved an inventive step – where primary judge found that the skilled person would be directly led to select compound disclosed in international patent publication as a lead candidate to take into further drug development work – where primary judge found that hypothetical skilled person would not have requisite expectation of success – whether primary judge applied incorrect legal test – error shown – appeal allowed

Legislation: Patents Act 1990 (Cth) s 7
Cases cited:

Aspirating IP Ltd v Vision Systems Limited (2010) 88 IPR 52; [2010] FCA 1061

AstraZeneca AB v Apotex Pty Ltd (2015) 257 CLR 356; [2015] HCA 30

Commissioner of Taxation v Peabody (1994) 181 CLR 359

Generic Health Pty Ltd v Bayer Pharma Aktiengesellschaft (2014) 222 FCR 336; [2014] FCAFC 73

Hanwha Solutions Corp v REC Solar Pte Ltd [2023] FCA 1017

Merck Sharp & Dohme Corporation v Wyeth LLC (No 3) (2020) 155 IPR 1; [2020] FCA 1477

Minnesota Mining & Manufacturing Company v Tyco Electronics Pty Ltd (2002) 56 IPR 248; [2002] FCAFC 315

Mylan Health Pty Ltd v Sun Pharma ANZ Pty Ltd (2020) 279 FCR 354; [2020] FCAFC 116

Nichia Corporation v Arrow Electronics Australia Pty Ltd (2019) 175 IPR 187; [2019] FCAFC 2

Otsuka Pharmaceutical Co Ltd v Generic Health Pty Ltd (No 4) (2015) 113 IPR 191; [2015] FCA 634

Pharmacia LLC v Juno Pharmaceuticals Pty Ltd (2022) 165 IPR 200; [2022] FCA 92

Pharmacia LLC v Juno Pharmaceuticals Pty Ltd (2022) 168 IPR 431; [2022] FCAFC 167

Sandoz AG v Bayer Intellectual Property GmbH [2023] FCA 1321

Wellcome Foundation Ltd v VR Laboratories (Aust) Pty Ltd (1981) 148 CLR 262

Division: General Division
Registry: Victoria
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Number of paragraphs: 121
Date of hearing: 16 & 17 May 2024
Counsel for the Appellants: Mr C Dimitriadis SC with Ms C Cunliffe
Solicitor for the Appellants: Ashurst
Counsel for the Respondents: Mr D Shavin KC with Ms K Beattie
Solicitor for the Respondents: Davies Collison Cave Law

ORDERS

VID 976 of 2023
BETWEEN:

SANDOZ AG

First Appellant

SANDOZ PTY LTD

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Sandoz AG v Bayer Intellectual Property GmbH and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2024] FCAFC 135
Decision Date

CaseChat Overview and Summary

In Sandoz AG v Bayer Intellectual Property GmbH, the Federal Court of Australia considered an appeal by Sandoz AG and Sandoz Pty Ltd against the decision of the primary judge in the Federal Court, which upheld the validity of two patents held by Bayer Intellectual Property GmbH and licensed to Bayer Australia Limited. Bayer Intellectual Property GmbH holds two Australian patents, No. 2004305226 (the 226 Patent) and No. 2006208613 (the 613 Patent), related to methods for producing a solid, orally applicable pharmaceutical composition and for the prevention and treatment of thromboembolic disorders, respectively. Sandoz sought to revoke these patents, arguing they were obvious in light of prior art, specifically International Patent Publication No. WO 01/47919 (WO 919) and certain abstracts published in the journal Blood.

The primary judge ruled in favour of Bayer, finding the patents valid and not obvious. The judge concluded that the skilled person could not reasonably be expected to have ascertained WO 919, and thus it could not be considered prior art under s 7(3) of the Patents Act 1990 (Cth). Additionally, the judge found that the inventions claimed in the patents involved an inventive step in light of the common general knowledge and the cited prior art. Sandoz appealed, arguing that the primary judge erred in both the ascertainment of prior art and the assessment of inventive step.

The court found that the primary judge erred in concluding that the skilled person could not reasonably be expected to have ascertained WO 919. The court clarified that the standard for ascertainment under s 7(3) requires a reasonable expectation on the balance of probabilities, not a certainty. The court held that the evidence established that the skilled person would have searched the patent database using relevant terms, and that WO 919 would have been included in the search results. The court also found that the primary judge applied an incorrect legal test when assessing the inventive step of the claimed inventions. The court held that the primary judge should have considered whether the skilled person would have had a requisite expectation of success in arriving at the claimed inventions, rather than whether they would have been directly led to the claimed compounds.

The court allowed the appeal, finding that the primary judge erred in both the ascertainment of prior art and the assessment of inventive step. The court set aside the primary judge’s decision and remitted the matter to the primary judge for reconsideration in light of the court’s findings. The parties were ordered to confer and supply draft short minutes of order to give effect to the court’s reasons within 10 days. If the parties could not agree, the areas of disagreement were to be set out in mark-up.

Orders

Orders of the court

1. Within 10 days, the parties confer and supply draft short minutes of order giving effect to these reasons.

2. Insofar as the parties are unable to agree to the terms of the draft short minutes of order referred to in order 1, the areas of disagreement should be set out in mark-up.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

This is an appeal from the decision of the primary judge in Sandoz AG v Bayer Intellectual Property GmbH [2023] FCA 1321 (J or judgment). Bayer Intellectual Property GmbH (Bayer) is the patentee of the two patents in suit: (1)Australian Patent No. 2004305226 entitled “Method for the production of a solid, orally applicable pharmaceutical composition” (the 226 Patent); and (2)Australian Patent No. 2006208613 entitled “Prevention and treatment of thromboembolic disorders” (the 613 Patent). Bayer Australia Limited (Bayer Australia) is, and has been since 14 February 2023, the exclusive licensee of the 226 Patent and the 613 Patent in Australia. Bayer Australia markets and sells Pharmaceutical Benefits Scheme listed products comprising rivaroxaban in Australia under the trade name XARELTO. Before the primary judge, Sandoz AG and Sandoz Pty Ltd (together, Sandoz) sought to revoke the 226 Patent and 613 Patent on various grounds, including that the inventions claimed:(1)in the 226 Patent and 613 Patent were obvious in the light of the common general knowledge together with International Patent Publication No. WO 01/47919 (WO 919); (2)in the 613 Patent were obvious in the light of the common general knowledge together with Abstracts 3003, 3004 and 3010 published in the November 2003 supplement of the journal Blood (the Blood Abstracts). The primary judge found that both the 226 Patent and the 613 Patent are valid: J [7]. A critical preliminary finding made by the primary judge to reach this conclusion insofar as it related to the allegations of lack of inventive step was a finding that the skilled person could not be reasonably expected to have ascertained WO 919 for the purpose of s 7(3) of the Patents Act 1990 (Cth): J [496]. Sandoz appeals from the judgment on the following three grounds (excluding the particulars):1.The primary judge erred in finding that a person skilled in the relevant art could not be reasonably expected to have ascertained International Patent Publication No. WO 01/47919 (WO 919) within the meaning of s 7(3) of the Patents Act 1990 (Cth) as applicable to the patents in suit (the Act) (at [432], [472]-[496]).2.The primary judge erred in finding that the inventions claimed in each of Australian Patent No. 2004305226 (the 226 Patent) and Australian Patent No. 2006208613 (the 613 Patent) involved an inventive step in the light of the common general knowledge (the CGK) together with WO 919 (at [591]-[623], [627]). 3.The primary judge erred in finding that the invention claimed [in] the 613 Patent involved an inventive [step] in the light of the CGK together with Abstracts 3003, 3004 and 3010 published in the November 2003 supplement of Blood (the Blood Abstracts) (at [638]-[671]). (Emphasis original.) For the following reasons, the appeal should be allowed.AGREED TERMINOLOGY Prior to the trial before the primary judge, the parties filed an agreed glossary and technical primer. Extracts from the agreed technical primer are included in the judgment. Some of these are set out below:(1)Absorption refers to the process by which an API (defined below) moves from the site of administration into a site in the body, usually the bloodstream. Absorption may be defined in terms of its rate and extent. For an orally administered API, the administration site is the gastrointestinal (GI) tract. In the case of a solid oral dosage form, the total extent of absorption may be determined by a number of factors, including the extent of release, solubility, permeability, local and pre-systemic metabolism, stability characteristics of the API in the GI tract and GI tract transit times. In the case of a solid oral dosage form, the rate of absorption may be determined by factors including the rate of release (including disintegration), dissolution rate, solubility, permeability, local and pre-systemic metabolism, rate of degradation (if any) of the API in the GI tract and the presence of food in the GI tract: J [14].(2)Anticoagulants are a class of antithrombotic drugs that inhibit the formation and/or propagation of coagulation, and/or the formation of fibrin, and are used in the treatment of thromboembolic disorders. By inhibiting the formation or growth of a clot, the anticoagulant allows the body time to break down the clot. Anticoagulants are also used prophylactically and chronically to decrease the risk of a new clot forming: J [18].(3)API means active pharmaceutical ingredient. The words “API” and “drug” can be used interchangeably: J [19].(4)Clot or thrombus consists of a mesh of fibrin that embeds activated platelets and red and white blood cells: J [25].(5)Coagulation cascade refers to a series of activation steps of various enzymes (factors) involved in coagulation. Under normal physiological conditions, it is only upon an injury that the coagulation system should rapidly and locally respond at an injured blood vessel wall to generate a clot: J [28].(6)Dosage form refers to the form in which the API is administered to the patient, such as tablets, capsules, solutions, suspensions, nasal sprays etc: J [34].(7)Dosage regimen refers to the regimen by which an API is administered, and includes the dose (quantity of API administered), dosage form, route (eg oral, intravenous, subcutaneous) and frequency of administration: J [35].(8)Factors refers to the main enzymes involved in the coagulation cascade: J [39].(9)Fibrin is the fibrous protein that makes up a clot or thrombus: J [40].(10)In vitro refers to analysis, tests or evaluations conducted outside a living organism (eg in a test tube): J [43].(11)Thromboembolism is a general term describing the combined processes of thrombosis (where a vessel is occluded by clots in part, or in entirety), or embolism (when a clot breaks off from the formation site and lodges elsewhere in the body). Thrombotic or thromboembolic disorders involve thrombosis and/or thromboembolism, which may develop in the venous or arterial circulatory systems: J [66].(12)Thrombosis is a pathological clot formation resulting in the obstruction of blood flow through a blood vessel. The primary mechanisms for thrombosis are the improper regulation of the coagulation cascade, and/or excessive platelet activation: J [67].

Ratio Decidendi

Legal Principle Established

After canvassing the circumstances in which Professor Roberts selected WO 919 from the spreadsheet of results, her Honour found at J [488] that the question of whether Professor Roberts would have selected WO 919 if he was provided with the full suite of results from searches undertaken across all his suggested databases and with broader search terms than just “factor Xa inhibitors” could not be answered on the evidence before her. The primary judge identified that there was no evidence as to how Professor Roberts would prioritise between different peer-reviewed journal articles, how he would prioritise as between journal articles and patents, and whether he might prioritise other antithrombotics over factor Xa inhibitors on the basis of the peer-reviewed articles located: J [488]. At J [489], the primary judge reiterated that the evidence did not establish that it would be reasonable for the person skilled in the art undertaking a search of the kind described by Professor Roberts but not restricted to factor Xa inhibitors to have found WO 919.Consideration The central issue in relation to ground 1 is whether the primary judge applied the correct standard for the purpose of determining whether a person skilled in the art could be reasonably expected to have ascertained WO 919. The standard imposed by s 7(3) does not require proof that the hypothetical skilled person would ascertain the document. Rather, it requires proof sufficient to demonstrate a reasonable expectation that the skilled person would do so, and that is on the balance of probabilities. As cited by Besanko J in Aspirating IP Ltd v Vision Systems Limited (2010) 88 IPR 52; [2010] FCA 1061 at [457], the High Court said in Commissioner of Taxation v Peabody (1994) 181 CLR 359 at 385:A reasonable expectation requires more than a possibility. It involves a prediction as to events which would have taken place if the relevant scheme had not been entered into or carried out and the prediction must be sufficiently reliable for it to be regarded as reasonable.(Footnotes omitted.) Further, as observed by Burley J in Pharmacia LLC v Juno Pharmaceuticals Pty Ltd (2022) 165 IPR 200; [2022] FCA 92 at [268]:Whether or not the prior art information can be reasonably expected to have been found depends on what the skilled person is likely to have done when faced with a problem similar to that which the patentee claims to have solved with the claimed invention. As to what the skilled person is likely to have done on the facts of this case, the evidence established, and the primary judge accepted, that the person skilled in the art would have conducted searches of (inter alia) the patent database using search terms including factor Xa inhibitors. Contrary to the submission by Bayer, it therefore does not matter that the skilled person would have also conducted searches using additional search terms. The evidence also established, and the primary judge accepted, that a search of the patent database would have returned results which included (inter alia) WO 919. Notably, the spreadsheet provided to Professor Roberts contained the full results of the search of the patent database albeit that not all of the information associated with each result was included.